DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more


Nutrilib.com
A comprihensive source of nutritional information

Multi-Centre European Photopatch Test Study

Information source: NHS Tayside
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Dermatitis, Photocontact

Intervention: 19 organic sunscreen filters and 5 topical NSAIDs (Drug)

Phase: N/A

Status: Not yet recruiting

Sponsored by: NHS Tayside

Official(s) and/or principal investigator(s):
James Ferguson, FRCP, Principal Investigator, Affiliation: NHS Tayside

Overall contact:
James Ferguson, FRCP, Phone: +44 (0) 1382 632240, Email: j.ferguson@dundee.ac.uk

Summary

It is known that people can develop an allergic skin reaction to a substance which is placed on the skin and then subjected to sunlight. This process is called Photocontact allergic dermatitis. It is known that people can develop Photocontact allergic dermatitis to sunscreen chemicals (filters) and also cream forms of pain-killing drugs called nonsteroidal anti-inflammatory drugs (NSAIDs).

The purpose of this study is to determine the frequency of Photocontact allergic dermatitis to 19 sunscreen filters and 5 topical NSAIDs in 1,000 European patients who present to a dermatologist with a sun-exposed site dermatitis.

Each participant will have the 24 test agents plus one control of petrolatum applied to the skin of the back for 24 or 48 hours. After removal of the substances, the area of skin will be exposed to a precise amount of ultraviolet-A light. The area is then assessed 24, 48 and 72 hours later to see if a photocontact allergic reaction has occured. This method is known as photopatch testing.

The study will run for one year, during which time it is planned to recruit 1,000 patients.

Clinical Details

Official title: A Prospective, Open, Multi-Centre Photopatch Test Study of Patients Suspected of Photoallergy to Organic Sunscreens and Topical Nonsteroidal Anti-Inflammatory Drugs Used Within Europe.

Study design: Diagnostic, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Single Group Assignment

Primary outcome: The development of a photocontact allergic skin response to sunscreen filters and topical NSAIDs, as graded by the ICDRG scale.

Detailed description: Specific Intervention Names:

- Butyl-methoxy-dibenzoylmethane

- Homosalate

- Methylbenzylidene camphor

- Benzophenone-3

- Octyl methoxycinnamate

- Phenylbenzimidazol sulfonic acid

- Benzophenone 4

- Drometrizole trisiloxane

- Octocrylene

- Octyl salicylate

- Octyl triazone

- Isoamyl-p-methoxycinnamate

- Terephtalidene dicamphor sulphonic acid (Mexoryl SX)

- Tinosorb S

- Tinosorb M

- Univul A+

- Neoheliopan AP

- Uvasorb HEB

- Parsol SLX

- Ketoprofen 1%

- Etofenamate 2%

- Piroxicam 1%

- Diclofenac 5%

- Ibuprofen 5 %

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male or female aged 18 years or older.

- Have sufficient cognitive capacity to give written informed consent.

- Have an eruption on photo-exposed sites, which is to be further classified using one

(or more) of the categories below:

- Known photosensitivity disease

- History of sunscreen reaction

- Sun exposed site dermatitis during summer months

- Any sun exposed site dermatitis problem

Exclusion Criteria:

- Male or female aged 17 years or younger

- Have had potent topical steroid applied to the photopatch test site on the back in the

previous 5 days. (This potentially suppresses reactions which would otherwise have been visible)

- Have skin disease on the back which is too active to allow testing. (This obscures the

sites of testing by making differentiation between a positive result and other skin disease difficult)

- Be prescribed systemic immunosuppressant medication (e. g. prednisolone, methotrexate,

azathioprine, ciclosporin) (This potentially suppresses reactions which would otherwise have been visible)

- Be taking any photoactive medicine (for example thiazides, sulphonamide derivatives,

amiodarone, fluoroquinolones, chlorpromazine, NSAIDs, quinine). (This is a relative exclusion. Many centres may wish to go ahead despite such medication).

Locations and Contacts

James Ferguson, FRCP, Phone: +44 (0) 1382 632240, Email: j.ferguson@dundee.ac.uk

Photobiology Unit, Ninewells Hospital,, Dundee, Angus DD1 9SY, United Kingdom
Additional Information

Starting date: July 2008
Ending date: July 2009
Last updated: May 22, 2008

Page last updated: November 03, 2008

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008